Quest raises outlook after completing Solstas buy; Svelte Medical Systems attracts another investor;

@FierceMedDev: Score for Georgetown U.--a team there developed a Dx that appears to predict the onset of Alzheimer's. Story | Follow @FierceMedDev

@MarkHFierce: Here are 10 M&A med tech deals announced or closed in 2013 set to have a real impact on the industry. Special Report | Follow @MarkHFierce

@MichaelGFierce: Boston Heart launches a new inflammation test for cardiovascular disease. More from FierceDiagnostics | Follow @MichaelGFierce

@EmilyWFierce: Not just for humans anymore: new medical devices for dogs measure everything from anxiety to activity level. Article | Follow @EmilyWFierce

> Quest Diagnostics ($DGX) raised its outlook for the year after completing its acquisition of Solstas Lab Partners. Story

> Svelte Medical Systems said it has attracted the Gary and Mary West Health Investment Fund as a new investor, another contributor to help fuel development of its new drug-eluting coronary stent integrated delivery system and rapid-exchange platforms. Item

> Derma Sciences, a company focused on tissue regeneration and wound care, will discuss its 2013 fourth quarter results on March 14. Item

> A small Chinese study compared two Medtronic ($MDT) cervical disc replacement implants, finding a short edge for the company's Accel device. Story

> A new implant that works like a pacemaker could help combat sleep apnea, according to a new study published in the New England Journal of Medicine. Story

Biotech News

@FierceBiotech: J&J partners with a biotech startup on a new approach to Alzheimer's. More | Follow @FierceBiotech

@JohnCFierce: I've seen plenty of instances of chutzpah in biotech, but these Northwest Bio claims cross a line into BS terrain. News | Follow @JohnCFierce

@DamianFierce: J&J, Pharmacyclics and the future of Big Pharma dealmaking. Story | Follow @DamianFierce

@EmilyMFierce: NIH faces flat funds under president's 2015 budget proposal . More | Follow @EmilyMFierce

> Regeneron, Sanofi and Amgen shares suffer on FDA's frets about PCSK9 class. Article

> Regado shares pop as drug wins fast-track status. Item

Pharma News

@FiercePharma: Top-read this weekend: Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year. Story | Follow @FiercePharma

@TracyStaton: RT from BioPharmaJosh: WSJ looks at how Johnson & Johnson beat out Novartis & Celgene for Imbruvica. Story via the Wall Street Journal (sub. req.) | Follow @TracyStaton

@EricPFierce: EMA wants warning on Ambien type drugs that landed Kerry Kennedy in court. More | Follow @EricPFierce

@CarlyHFierce: AstraZeneca says Nexium pills with Ranbaxy ingredient are safe to use. Article | Follow @CarlyHFierce

> A key Actos trial revs up in Vegas with demands for a $1B-plus judgment. News

> Novartis orphan drug Jakavi nabs 'blockbuster' forecasts on new data. Piece

> Long-acting hemophilia meds portend a pricing fight with older drugs. More

Biotech IT News

> Illumina backs Venter's plan to create world's largest human genome sequencing center. Story

> Big Data, social media and mobile double their share of biopharma marketing mix. Report

> Google-backed genomics alliance details data interoperability plans. Story

> FDA informatics chief: NGS is an immediate priority for the agency. Article

> Scripps shares genetic sequences of healthy elderly to boost Alzheimer's and cancer research. Article

> Eli Lilly begins sharing photos on Instagram. Brief

CRO News

> WuXi soars on manufacturing and plots another leap in 2014. Story

> INC buys its way into the Middle East with MEK deal. Article

> Celerion stretches into South Korea for translational studies. Story

> Harlan partners up for early-stage drug development. News

> Columbia Labs inches forward in its first quarter as a CRO. Story

> Quintiles' bankrollers eye another $1B in second offering. Brief

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.